Soligenix,Inc granted an ILAP ‘Innovation Passport’

Kinesys is very pleased to announce that our long-term client Soligenix, Inc. has been granted an ILAP ‘Innovation Passport’ by UK MHRA for the company’s novel HyBryte treatment for Cutaneous T-Cell Lymphoma (CTCL). We are delighted to have supported Soligenix, Inc. with this application, one of the first ILAPs approved. This follows on from the successful Phase 3 trial of HyBryte announced at the end of 2020. CTCL is a serious disease affecting the skin and which, in later stages, becomes a systemically, progressive condition that is ultimately life-threatening

Written By gerry mcgettigan